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A B S T R A C T
Radiotherapy (RT) is the major modality for control of glioblastoma multiforme (GBM), the most aggressive
brain tumor in adults with poor prognosis and low patient survival rate. To improve the RT eﬃcacy on GBM, the
mechanism causing tumor adaptive radioresistance which leads to the failure of tumor control and lethal pro-
gression needs to be further elucidated. Here, we conducted a comparative analysis of RT-treated recurrent
tumors versus primary counterparts in GBM patients, RT-treated orthotopic GBM tumors xenografts versus
untreated tumors and radioresistant GBM cells versus wild type cells. The results reveal that activation of STAT3,
a well-deﬁned redox-sensitive transcriptional factor, is causally linked with GBM adaptive radioresistance.
Database analysis also agrees with the worse prognosis in GBM patients due to the STAT3 expression-associated
low RT responsiveness. However, although the radioresistant GBM cells can be resensitized by inhibition of
STAT3, a fraction of radioresistant cells can still survive the RT combined with STAT3 inhibition or CRISPR/
Cas9-mediated STAT3 knockout. A complementally enhanced activation of ERK1/2 by STAT3 inhibition is
identiﬁed responsible for the survival of the remaining resistant tumor cells. Dual inhibition of ERK1/2 and
STAT3 remarkably eliminates resistant GBM cells and inhibits tumor regrowth. These ﬁndings demonstrate a
previously unknown feature ofSTAT3-mediated ERK1/2 regulation and an eﬀective combination of two targets
in resensitizing GBM to RT.
1. Introduction
GBM remains as a critical clinical issue with the worst prognosis and
unacceptable low survival rate after diagnosis [1,2]. RT is one of the
major post-surgical modalities for the local control of GBM; however,
the eﬃcacy of RT is limited by the tumor adaptive radioresistance.
Radioresistant cells in solid tumors including GBM are enriched with
cancer stem cells (CSCs) and linked with cancer adaptive resistance
[3,4]. CD133, a marker for brain tumor stem cells [5,6], is enhanced in
radiation treated GBM [7], and CD133+ GBM cells isolated from
human specimens are more eﬃcient in repairing DNA damage than that
in CD133- cells [8]. However, to signiﬁcantly improve the eﬃcacy of RT
in GBM treatment, the molecular insights causing the resistance phe-
notype of GBM cells are to be elucidated.
STAT3 is a well-deﬁned redox-sensitive oncogenic transcription
factor [9–11] and plays a key role in the maintenance of the stemness of
CD133+ tumor cells including GBM cells [12,13]. Abundant expression
and persistent activation of STAT3 are identiﬁed in cancer cells con-
ferring tumor resistance and aggressive progression [14–18]. Anti-
tumor treatment-induced STAT3 activation has also been observed in a
variety of tumor cells. Therapeutic approaches targeting HER2 [19],
EGFR [20,21], MEK-ERK [22], ALK and MET [20] are found to induce
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STAT3 activation causing tumor adaptive resistance. In addition, ra-
diation promotes STAT3 activation and nuclear translocation to en-
hance GBM malignancy [23]. Considering the important roles in
maintaining the stemness and enhancing radioresistance of tumor cells
[24], STAT3 is a promising target with increasing speciﬁc inhibitors
being invented and entered in clinical trials for treatment of diverse
human cancers, including being developed to enhance temozolomide-
mediated radiosensitization [25]. However, the speciﬁc eﬃcacy of
targeting STAT3 in the treatment of radioresistant GBM rumors remains
unclear.
ERK1/2 is another fundamental pro-surviving factor in mammalian
cells. Increasing evidence suggests that ERK1/2-dependent RAF/MEK/
ERK1/2 pathway is essential in promoting tumor progression and
mediating resistance to anti-tumor therapies by various mechanisms
[26]. Recently, RAF inhibition-mediated ERK activation similar to
therapies-induced STAT3 feedback loop activation is linked with tumor
growth [27]. It has been reported that ERK1/2 enhances STAT3
Serine727 phosphorylation whereas dephosphorylates STAT3 at Tyr-
osine 705 [28]. In addition to Serine727, ERK1/2 phosphorylates
STAT3 on other two serine residues involving in the reduction of tyr-
osine705 phosphorylation and DNA binding activity [29]. As such, al-
though ERK1/2 signaling pathway has been extensively studied, it re-
mains unclear whether pSTAT3 (Y705) aﬀects ERK1/2 activation in
tumor cells, especially in radioresistant GBM cells.
Here we reveal that activation of STAT3 is predominantly enhanced
in CD133-enriched radioresistant GBM cells and recurrent tumors.
However, surprisingly, although blocking of STAT3 increases the sen-
sitivity of resistant GBM cells to radiation, STAT3 inhibition-mediated
ERK1/2 activation promotes cell survival and repopulation under ra-
diation treatment. A synergetic administration of ERK1/2 inhibitors can
eﬀectively eliminate resistant GBM cells and suppress GBM tumor re-
growth post RT. As such, we demonstrate that a combinational in-
hibition of STAT3 and ERK1/2 may be a novel and eﬃcient strategy for
GBM radiotherapy.
2. Materials and methods
2.1. Cell lines and culture conditions
Human GBM U251 and U87 cells, breast cancer MCF7 and MDA-
MB-231 cells were purchased from ATCC. U251 cells were maintained
in MEM medium (CORNING Cellgro, Catalog # 10-010-CV) containing
10% FBS (CORNING, Catalog # 35-010-CV), 0.1 mM NEAA (CORNING
Cellgro, Catalog # 25-025-CI), 1 mM sodium pyruvate (CORNING
Cellgro, Catalog # 25-000-CI) and 10mM Hepes (VWR, Catalog #
97064-360); U87, MCF7 and MDA-MB-231 cells were maintained in
DMEM medium (CORNING Cellgro, Catalog # 10-013-CV) with 10%
FBS. Human astrocytes HA1800 were maintained in DMEM supple-
mented with 10% FBS. Radioresistant clones of U251 or U87 cells were
derived from the corresponding wild-type cells after a chronically ir-
radiation (2 Gy per workday for 20 days) and cells from U251/C7 were
veriﬁed with radioresistance and used as radioresistant cells in the
subsequent experiments, medium formula for maintaining radio-
resistant cells was the same as the parental cells. Radioresistant H157R
and H358R cells were kindly gifted from Xingming Deng (Winship
Cancer Institute of Emory University) [30] and were maintained in
RPMI-1640 medium (Hyclone) with 10% FBS.
2.2. Antibodies and reagents
Antibodies used in this study wereCD133 (IHC: BOSTER, PA2049;
WB, Miltenyi Biotec, 130-092-395), pSTAT3 (Y705) (IHC, IF, IP and
WB: Cell Signaling Technology, 9145), STAT3 (WB: Cell Signaling
Technology, 4904), pERK1/2 (IHC, IF and WB: Cell Signaling
Technology, 4370), CBP (WB: Santa Cruz Biotechnology, sc-369), RSK-
1 (WB: Santa Cruz Biotechnology, sc-231), c-Myc (WB: Cell Signaling
Technology, 9402s), c-fos (WB: Santa Cruz Biotechnology, sc-253), Ets-
1 (WB: Santa Cruz Biotechnology, sc-111), p-GSK 3β (Ser9) (WB: Cell
Signaling Technology, 5558), GSK 3β (WB: Cell Signaling Technology,
9315s), ERK1/2 (IP and WB: Cell Signaling Technology, 4695),
phospho-mTOR (Ser2448) (WB: Cell Signaling Technology, 2971),
mTOR (WB: Cell Signaling Technology, 2983), phospho-AKT (Ser473)
(WB: Cell Signaling Technology, 9271), AKT (WB: Cell Signaling
Technology, 9272), α-tubulin (Sigma-Aldrich, T6074), rabbit IgG (IP:
Santa Cruz Biotechnology, sc-2027), anti-rabbit IgG (WB: Cell Signaling
Technology, 7074s) anti-mouse IgG (WB: Cell Signaling Technology,
7076s).
Selective pSTAT3 (Y705) inhibitors Cryptotanshinone (Catalog
#S2285), S3I-201 (Catalog #S1155), Stattic (Catalog #S7024),
WP1066 (Catalog #S2796), STAT1 activation inhibitor Fludarabine
(Catalog #S1491), MEK1/2 inhibitors U0126 (Catalog #S1102) and
Selumetinib (AZD6244, Catalog #S1008) were purchased from
Selleckchem. Anexin IV (Catalog # ANNEXINV01-3) was bought from
CaltagLaboratories, propidium iodide (PI, Catalog #L7010) was bought
from Invitrogen. Cycloheximide (CHX, Catalog #C7698) and dimethyl
sulfoxide (DMSO, Catalog #D2650) were bought from Sigma-Aldrich.
DAPI Fluoromount-G (Catalog # 0100-20) was bought from
SouthernBiotech.
2.3. Immunoprecipitation and immunoblotting analyses
Proteins extracted with a modiﬁed buﬀer from cells were followed
by immunoprecipitation and immunoblotting detection with corre-
sponding antibodies, as previously described [31]. Three independent
experiments were done in triplicate.
2.4. Luciferase reporter gene assay
Transcriptional activation of STAT3 in GBM cells was measured as
previously described except for slight modiﬁcations that no cytokine
treatment was applied in this study [32]. Three independent experi-
ments were performed in triplicate.
2.5. Immunohistochemical analysis
Mouse tumor tissues were ﬁxed and prepared for im-
munohistochemistry (IHC) or haematoxylin and eosin (HE) staining.
For IHC analysis, the specimens were stained with antibodies against
CD133, pY705-STAT3, pERK1/2 or cleaved-caspase 3. For HE analysis,
the specimens were stained with Mayer's haematoxylin and subse-
quently with eosin (Biogenex Laboratories).
The tissue sections from paraﬃn-embedded 34 paired human GBM
specimens were stained with an antibody against CD133 or pY705-
STAT3. 3–5 sections of each sample and 5–6 high-power ﬁelds (HPF) of
each section were used for analysis and quantiﬁcation. The tissue sec-
tions were quantitatively scored according to the staining intensity (0,
negative; 1, slight yellow; 2, brown; 3, dark brown) and percentage of
positive stained cells (0, ≤10%; 1, 10%–25%; 2, 25%–50%; 3,
50%–75%; 4,≥75%) with a scoring scale ranging from 0 to 12, protein
expression in tumor tissues was graded as negative (0); low/weak
(1–4); moderate (5–8); high/strong (9–12), respectively. Scores of re-
current samples were compared with the corresponding primary
counterparts from the same patients, of which 27 out of 34 patients
received post-surgical RT. The use of human brain tumor specimens and
database was approved by Human Ethic Committee of Xiangya Hospital
of Central South University. In determining the eﬀects of treatments on
the indicated proteins in xenografts, alterations of the percentage of
positive cells in mice tumor tissues before or after treatments were
employed instead of H-score. Similarly, 3 sections of each tumor and
5–6 HPF of each section were used to count the percentage of protein-
expressing cells (no staining, negative; slight yellow, brown or dark
brown, positive).
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2.6. CRISPR/Cas9-based STAT3 knockout
The sgRNAs were designed following the instruction published by
Dr. Zhang Lab's CRISPR design software (http://crispr.mit.edu) and the
established protocol that has been described in previous publication
[33]. Six oligos were designed corresponding to the human sgRNAs
were synthesized and cloned into lentiCRISPR v2 vectors from the
Addgene plasmid repository (plasmid#52961) following the Zhang Lab
GeCKO pooled library ampliﬁcation protocol. To minimize the possi-
bility of nonspeciﬁc targeting, three sgRNAoligos of each targeting gene
were synthesized and tested. The sgRNA with the best knockout eﬃ-
ciency determined by western blotting was chosen for the subsequent
experiments. The sgRNA sequences are as follows:
LentiCrispr V2/hSTAT3gRNA #1 (032) F: CACCGATCGGCCGGTG
CTGTACAAT
LentiCrispr V2/hSTAT3gRNA #1 (032) R: AAACATTGTACAGCAC
CGGCCGATC
LentiCrispr V2/hSTAT3gRNA #2 (033) F: CACCGACGCCGGTCTT
GATGACGAG
LentiCrispr V2/hSTAT3gRNA #2 (033) R: AAACCTCGTCATCAAG
ACCGGCGTC
LentiCrispr V2/hSTAT3gRNA #3 (034) F: CACCGGTGATACACCTC
GGTCTCAA
LentiCrispr V2/hSTAT3gRNA #3 (034) R: AAACTTGAGACCGAGG
TGTATCACC
The lentiviral particles were generated using 293T cells following
the protocol from Addgene. For gene editing, U251/C7 cells were
trypsinized into single cell suspension and were plated 1.25×105
cells/0.5 ml per well in 12-well plates. 1 ml of virus-containing super-
natant with 10 ng polybrene (Sigma-Aldrich, Catalog #H9268-10G)
was added to the cells 12 h after incubation. Then, 0.5ml additional
regular medium containing 10% heat-inactive FBS was added 6 h after
incubation and cultured for overnight. The infection medium was re-
placed with 2ml fresh medium with 10% FBS and cultured for 72 h.
Cells were passaged to 60mm dishes and selected by culturing in
0.3 μg/ml puromycin for 1 week and the knockout of targeted gene was
veriﬁed by immunoblotting.
2.7. Establish cell lines expressing wild-type or mutant STAT3
The expression plasmids, Wild-type STAT3, mutant STAT3 (Y705F),
and control vectors were kindly provided by T Hirano [34]. 5× 105
U251/clone7 cells in 6-well plate were transfected with 1ml wild-type
STAT3 or STAT3 (Y705F) virus medium containing 80 μg/ml poly-
brene, similarly as previously described [34]. After 6 h, 0.5ml fresh
complete medium was added to cells followed by further 10 h incuba-
tion, then replace with fresh medium. 1 μg/ml puromycin was added to
cells in 24 h for 1 week to select out resistant cells. The expression of
wild-type STAT3 and mutant STAT3 Y705F in cells were determined by
immunoblotting.
2.8. Tumor sphere formation assay
Cells were sieved with 40 μm cell strainers (Fisher) and single-cell
suspensions were seeded into low-attachment 60mm Petri dishes at a
density of 500 cells/ml. Cells were grown in serum-free MEM medium,
supplemented with B27 (Life Technology), 20 ng/ml EGF (Biovision),
20 ng/ml basic-FGF, and 4 μg/ml heparin (VWR). Cells were cultured
for 5 days and tumor spheres were counted, sphere size were measured
and calculated under light microscopy and collected for further ex-
periments. Three independent experiments were done in triplicate.
2.9. Apoptosis analyses
For Sub-2N analysis, 2× 105-trypsinized cells were collected and
washed with PBS twice. Add 100 μl incubation buﬀer (1× PBS
containing 0.5% BSA) to resuspend pellets. Then cells were stained with
5 μl propidium iodide by 10min incubation at room temperature (keep
in dark) and 100 μl incubation buﬀer was added to cells before cell
death was analyzed using a variation of a conventional FACS method
(Millipore, Temecula, CA, USA) to detect sub-2N DNA content which
represents cells undergoing apoptosis [35,36]. For Annexin-V/PI
staining, U251/C7 cells were incubated with DMSO, cryptotanshinone,
selumetinib, U0126, cryptotanshinone plus selumetinib or cryptotan-
shinone plus U0126 for 4 h, followed with 5 Gy radiation exposure and
kept in incubator for additional 48 h. Cells in supernatant and in ad-
herent growth were collected and washed with PBS twice, then stained
with Annexin-V/PI. Cell death was determined by FCA and analyzed
with FlowJo.
2.10. Kaplan-Meier survival analyses
TCGA RNA-seq data for GBM, gliomas and breast cancer samples
were obtained from UCSC Xena browser (http://xena.ucsc.edu/). The
overall survival and relapse-free survival were evaluated using the
Kaplan–Meier method, and statistical diﬀerences in survival times were
determined using the log-rank test as described elsewhere. The cohort
include 720 lung adenocarcinoma samples obtained from Kaplan-Meier
Plotter (http://kmplot.com/analysis/index.php?p=service&cancer=
lung) were used to generate the overall survival analyses of lung ade-
nocarcinoma based on STAT3 (Aﬀy ID, 208992_s_at) status. A log rank
test was used to test for diﬀerences of more than one survival curve.
2.11. In vivo experiments
2.11.1. Orthotopic model
NSG mice aged 6 weeks were obtained from The Jackson Laboratory
(Stock No: 005557). The animal use and care protocol of in vivo RT was
approved by the Institutional Animal Use and Care Committee of the
University of California Davis (IACUC 15315). For orthotopic xeno-
grafts, wild-type U251 cells were trypsined, washed twice with PBS and
resuspended in PBS (5× 106 cells/50 μl) for the following use. NSG
mice (n=3 per group) were anesthetized with ketamine and xylazine.
5 μl of 5× 105 U251 cells were stereotactically and intracranially in-
jected through an entry site located 1.5 mm posterior to the bregma and
1.5 mm to the right of the sagittal suture to a depth of 2.5mm below the
surface of the skull using a 10-μL Hamilton syringe. Tumors developed
8 days after cell injection, and mice were received 2 Gy/day local RT for
5 days (day 8, day 9, day 10, day 11 and day 12). Magnetic Resonance
Imaging (MRI) examinations of mice brain were performed at day 8,
day 20 and day 58 after cell injection.
2.11.2. Subcutaneous model
For the subcutaneous tumor inoculation, 5× 106 wild-type
U251 cells in 200 μl PBS were injected into 6 weeks old female nude
mice (The Jackson Laboratory, Stock No: 002019) in the right ﬂanks
(n= 7 per group). Tumor volumes were estimated and calculated using
the formula for a spheroid: V= Length x width2/2. Tumors were pro-
truded for fractionated irradiation (2 Gy/day) when tumor volumes
reached approximately 200mm3 (tumors received radiation at day 16,
day 17, day 18, day 19 and day 20, respectively). Tumor volumes
shrank but re-reached approximately 200mm3 8 days after RT, and the
regrowing tumors were used as radioresistant tumors.
Cryptotanshinone (25mg/kg, 20 mg/ml in 25 μl DMSO), selumetinib
(25mg/kg, 20mg/ml in 25 μl DMSO) or cryptotanshinone combined
with selumetinib was then intratumorally injected 4 h before tumors
receiving RT (2 Gy/day for 2 days). The inhibitors were administered
every other day till the end of experiment. Tumor volumes were esti-
mated and calculated at the indicated times.
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Fig. 1. Activation of STAT3 correlates with GBM radioresistance. (A) Representative IHC staining of pSTAT3 (Y705) and CD133 in paired primary and recurrent
tumors. Scale bar, 100 μm. (B) IHC scores distribution of pSTAT3 (Y705) (right) and CD133 (left) in 34 paired (primary and recurrent tissues from the same patient)
tumors. Mean ± SD, ***P < 0.001, ****P < 0.0001. (C) Related pSTAT3 (Y705) expression levels evaluated by N-H scales (N, negative; L, low; M, moderate; H,
high). E, enhanced; U, unchanged; R, reduced. (D) Above, orthotopic U251 xenograft tumors treated by local radiation with 2 Gy daily for 5 days, sham radiation was
used as control. Bottom, MRI imaging of mice brain at day 8, day 20 or day 58. (E) Left, representative HE and IHC of CD133 and pSTAT3 (Y705) in sham or regrown
orthotopic GBM tumors. Right, quantiﬁcation of CD133 and pSTAT3 (Y705) in sham and regrown tumors. Mean ± SD, ***P < 0.001. (F) Kaplan-Meier estimates of
the overall survival (OS) of GBM patients from TCGA related to STAT3 transcript levels. (G) Kaplan-Meier analysis of the relapse-free survival (RFS) of TCGA patients
based on transcriptional STAT3expression status (high expression, red line, n= 259; low expression, black line, n=260). P=0.0008. (H) Kaplan-Meier analysis of
GBM patients with or without RT whose tumor expressed high or low STAT3. (I) Statistically signiﬁcant diﬀerence in (H). Patients with diﬀerent STAT3 status treated
with or without RT were analyzed. (J) RFS proportions at 10, 20 or 30 month of patients in (H).
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2.12. Statistical analysis
Data in this study are presented as mean ± SD, and analyzed using
the two-tailed Student t-test for two groups or ANOVA for multiple
groups. The statistical signiﬁcance of Kaplan–Meier survival curves was
assessed with a Mann-Whitney test. A value of p less than 0.05 was
considered as statistically signiﬁcant. *P < 0.05, **P < 0.01,
***P < 0.001.
3. Results
3.1. STAT3 activation is enhanced in recurred GBM tumors and diverse
radiation-survived tumor models
To examine whether activation of STAT3 (pSTAT3 Y705) was re-
lated to the radioresistance and recurrence of GBM tumors, we ﬁrstly
analyzed 34 paired clinical GBM samples of both primary and recurrent
tumors from the same patients; most of them received RT. pSTAT3
(Y705) was enhanced in recurrent tissues (26 out of 34 patients, 76.5%)
compared with their corresponding primary counterparts (Fig. 1A–C
and Supplementary Table 1). In addition, more than 90% of recurrent
tumors were positive in both CD133 and pSTAT3 (Y705)
(Supplementary Table 2). Indicating that pSTAT3 (Y705) is potentially
related to GBM radioresistance and recurrence.
Based on this result, to further explore the dynamic features of
STAT3 in GBM response to radiation, we employed two approaches.
First, NSG mice were intracranially injected with wild-type U251 cells
and followed by sham or fractionated local radiation at day 8 post in-
oculation. The tumors received radiation treatment shrunk at day 20
and regrowth was observed at day 58 (Fig. 1D). In consistence with the
increase of CD133 and pSTAT3 (Y705) in recurrent clinical GBM tis-
sues, the regrown GBM xenografts in mouse brains showed enhanced
CD133 and pSTAT3 (Y705) staining compared with the parallel tumors
received sham RT (Fig. 1E). Second, we established diverse in vitro
models to monitor the dynamic alteration of pSTAT3 (Y705) in tumor
cells before and after receiving clinically mimic fractionated ionizing
radiation (2 Gy per workday for 20 days). The cells from 6 out of 7
survived U251 clones revealed signiﬁcant enhancement of CD133 and
pSTAT3 (Y705) expression compared to the parental cells
(Supplementary Figs. 1A and B). Among the CD133-expressing cells,
clone7 (U251/C7) showed the highest enrichment of pSTAT3 (Y705)
and were more aggressive and radioresistant comparing with the par-
ental counterparts (Supplementary Figs. 1C–E). Similarly, we observed
enhancement of STAT3 activation and CD133 expression in U87 clones
survived chronic radiation as U251 cells (Supplementary Fig. 1F).
Analogously, pSTAT3 (Y705) was induced in breast cancer MCF7 cells,
lung cancer H358 and H157 cells after fractionated radiation
(Supplementary Fig. 1G). In addition to the changes of molecular
characteristics, the survived clones of U251 and U87 exhibited more
‘aggressive’ morphology, which was completely diﬀerent from their
parental cells, except U251/C1, the only survived clone that shows no
increase of STAT3 activation (Supplementary Figs. 1H and I). Recent
studies have revealed the relationship between therapeutic resistance
and cell morphology alterations [37]. Thus, the morphology plasticity
of GBM cells survived radiation may represent a dominant phenotype in
adaptation to rewired molecular circuit. Moreover, similar median
STAT3 expression was observed in over 30 GBM cell lines including
U251 and U87 cells compared with clinical GBM tumors, both of which
were much higher than that in normal brain tissues (Supplementary
Figs. 2A and B). Thus, together with literatures [38,39], these data
strongly suggest that STAT3 correlates with the malignancy and
radioresistance of GBM tumors.
3.2. STAT3 is associated with poor prognosis in GBM
Since recurrent clinical GBM tissues and recurred orthotopic GBM
tumors demonstrated robust STAT3 activation compared with the cor-
responding primary counterparts and sham-irradiated tumors, respec-
tively, we next uncovered the relationship between STAT3 expression
and GBM prognosis. We performed Kaplan-Meier survival analysis of
GBM patients in TCGA based on STAT3 status. Comparing with low
STAT3 expression in tumor tissues, high levels of STAT3 were positively
associated with poorer overall survival (OS) (P=0.0099) in general
(Fig. 1F). Particularly, patients with high STAT3 expression achieved
OS by 63.6%, 24.5% and 8.8% at 10, 20 and 30 months, respectively,
while the OS of those with low STAT3 expression was correspondingly
67.7%, 36.4% and 19.5% (Supplementary Fig. 2C). Similar signiﬁcant
diﬀerence was observed in relapse-free survival (RFS) between patients
with high or low expression of STAT3 (P=0.0008) (Fig. 1G and
Supplementary Fig. 2D).
To further determine the correlation between STAT3 expression and
GBM radioresistance, we analyzed the eﬀect of STAT3 on the radiation
response of GBM based on the clinical information from TCGA data-
base. Almost no diﬀerence of RFS probability was observed in patients
without RT probably due to the short median survival time, while im-
proved RFS was obtained in patients received RT (P < 0.0001)
(Fig. 1H and I). However, importantly, patients with elevated STAT3
expression had signiﬁcantly reduced RFS (59.6%, 20.7% and 9.8% at
10 month, 20 month and 30 month, respectively) compared with those
expressing low STAT3 (achieved 70.8%, 37.6% and 21.1% of RFS
proportions at 10 month, 20 month and 30 month, respectively)
(P=0.0007) (Fig. I and J). Similarly, STAT3 status was also linked to
prognostic signiﬁcance for the OS of patients with glioma
(P=1.84× 10−13), breast cancer (P=0.0005) or lung adenocarci-
noma (P=4.9× 10−6) (Supplementary Fig. 2E).
3.3. Radioresistant GBM cells survive radiation in the presence of STAT3
inhibition
To further examine the eﬀect of radiation on STAT3 in GBM, we
performed a range of tests in several relevant in vitro systems, and
found that STAT3 activation was inducible in radioresistant GBM cells
by radiation stimulation (Fig. 2A). STAT3 activation could be eﬃciently
inhibited by speciﬁc inhibitors including cryptotanshinone (inhibition
of phosphorylation of STAT3 tyrosine705; Supplementary Fig. 3A)
[40], an inhibitor extracted from Danshen, which has been used as an
Asian medicine in cardiovascular disorders [41]. And subsequently
radioresistant U251/C7 cells were used to test the blocking eﬃcacy of
STAT3 transcriptional activity and radiation sensitization. Cells were
incubated with cryptotanshinone, or other STAT3 inhibitors including
WP1066 [42,43] (inhibition of JAK2 and STAT3 activation) and S3I-
201 [44,45] (inhibition of phosphorylation of STAT3 tyrosine 705 and
its DNA-binding activity) in the presence or absence of 5 Gy radiation
treatment (Fig. 2B and C). Though blocking STAT3 activation reduced
the clonogenicity of U251/C7 cells, we observed that 10%–30% cells
could not be eradicated by the combinational treatment with radiation
and STAT3 blockade. For further conﬁrmation, we knocked out STAT3
in U251/C7 cells via CRISPR/cas9-mediated gene editing (Fig. 2D) and
exposed cells to 5 Gy radiation. Likewise, comparing with STAT3-ex-
pressing control cells, the clonogenic survival of STAT3-deﬁcient
CD133+ cells reduced to 12%∼22% which was doggedly preserved for
repopulation (Fig. 2E). These reductions could be rescued by recon-
stitution with wild-type STAT3, but not with re-expressing dominant
negative mutant STAT3 (Y705F, tyrosine705 to Phenylalanine 705)
(Fig. 2F). In addition, we observed that removal of STAT3 inhibitor
roused the well-preserved proliferative capability of cells retarded with
STAT3 blockade (Supplementary Fig. 3B). Interestingly, despite of re-
duced spheres number, U251/C7 cells formed loose spheres with larger
size in the presence of STAT3 inhibitor cryptotanshinone
(Supplementary Fig. 3C).
We had observed that a small portion of adherent U251/C7 cells
detached within 24 h after exposure to STAT3 inhibitors. These
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detached cells could not re-adhere by refreshing with complete
medium. It seemed reasonable to propose that the detached cells were
more sensitive to STAT3 inhibition than those of adherent cells. To
understand the underlying mechanisms, we incubated U251/C7 cells
with cryptotanshinone for 24 h, the detached and adherent cells were
then collected respectively and extracted for proteins immediately.
Interestingly, the phosphorylated mTOR (Serine2448) and ERK1/2
(Threonine 202/tyrosine 204), two of the well-studied essential factors
persistently activated in multiple tumors and interplayed with STAT3
for tumor survival, were both increased by more than 3 folds in ad-
herent cells compared to detached cells while CD133 and phosphory-
lated AKT (Ser473) almost remain the same levels (Fig. 2G).
Fig. 2. A fraction of radioresistant GBM cells survives STAT3 inhibition with ERK1/2 activation. (A) STAT3 luciferase reporter activity in wild-type and
radioresistant U251/C7 cells 24 h after sham or 5 Gy radiation. Mean ± SD, *P < 0.05, **P < 0.01; ns, no signiﬁcance. (B) STAT3 reporter activity in U251/C7
cells 24 h after incubation with DMSO, Cryptotanshinone (Crypto, 10 μM; STAT3 inhibition), WP1066 (5 μM; STAT3 inhibition) or S3I-201 (50 μM; STAT3 in-
hibition). Mean ± SD, ***P < 0.001. (C) Clonogenic survival of U251/C7 cells treated with sham or 5 Gy IR and cryptotanshinone (10 μM), WP1066 (5 μM) or S3I-
201 (50 μM). Mean ± SD, **P < 0.05, ***P < 0.001. (D) Conﬁrmation of STAT3-deﬁcient cell lines (#1, #2 and #3) generated by CRISPR/cas9-mediated
knockout in U251/C7 cells. (E) Left, representative image of surviving clones of STAT3-knockoutcells (#1, #2 and #3) with or without IR (5 Gy). Right, quanti-
ﬁcation of the surviving clones (Insert, immunoblotting of CD133 and pSTAT3 (Y705) in indicated surviving clones). Mean ± SD, *P < 0.05, **P < 0.01,
***P < 0.001. (F) Clonogenic survival of STAT3-knockout #3 cells rescued with vector, mutant STAT3 (Y705F, tyrosine to Phenylalanine) or wild-type STAT3 and
treated with sham and 5 Gy IR. Mean ± SD, ***P < 0.001). (G) U251/C7 cells were exposed to cryptotanshinone (10 μM) for 24 h, the detached cells and adherent
cells were then collected for protein extraction, separately (above schematic). CD133, phosphorylated mTOR (Ser2448), AKT (Ser473) and ERK1/2 were detected by
western blot (bottom left) and quantiﬁed by ImageJ for 4 times (bottom right) and normalized to α-tubulin. Data are representative of three independent experi-
ments. Mean ± SD, ***P < 0.001; ns, no signiﬁcance.
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Hyperresponsive ERK1/2 signaling was reported to phosphorylate
mTOR at serine2448 via S6K1 to regulate cell growth and survival [46].
Our data suggest that, despite STAT3 inhibition increases the sensitivity
of partial resistant cells to radiation treatment, a proportion of cells can
endure combinational treatment of radiation and STAT3 inhibition
potentially due to the activation of other molecular pathways, at least
ERK1/2 signaling.
3.4. ERK1/2 activation mediates resistance to STAT3 inhibition in
radioresistant GBM cells
To investigate whether inhibition of STAT3 leads to activation of
ERK1/2 pathway, we ﬁrst tested the basal phosphorylated ERK1/2
(pERK1/2) in orthotopic xenografts. IHC staining shows that pERK1/2
was higher in wild-type tumors [pSTAT3 (Y705) low] than that in tu-
mors regrown from fractionated RT [pSTAT3 (Y705) high)]
(Supplementary Fig. 4A). Also, comparing with normal brain tissues,
GBM tumors exhibited reduced expression of ERK1/2 and upstream
kinases, increased STAT3 and STAT3 downstream genes expression
(Supplementary Fig. 4B). To further determine whether STAT3 inhibi-
tion aﬀected ERK1/2 activity, U251/C7 cells were challenged with
cryptotanshinone. Comparing with DMSO incubation, exposure to
cryptotanshinone immediately and signiﬁcantly enhanced ERK1/2
phosphorylation, which was observed at 0.5 h post treatment and sus-
tained to 24 h (Fig. 3A and Supplementary Fig. 5A). Implying that
pSTAT3 (Y705) inhibition-mediated enhancement of ERK1/2 phos-
phorylation may not depend on the transcriptional activity of pSTAT3
(Y705). Once pSTAT3 (Y705) was blocked, the nuclear translocation of
active ERK1/2 was increased (Fig. 3B). Similar increase of ERK1/2
phosphorylation was ascertained in U251/C7 cells treated with other
STAT3 inhibitors, such as SH5-07, S3I-201, stattic and WP1066,
whereas no alterations of ERK1/2 phosphorylation were observed in
those treated with DMSO or STAT1 inhibitor ﬂudarabine (Fig. 3C). In
addition to U251/C7 cells, the ERK1/2 phosphorylation in other
radioresistant GBM cells such as U87/S8, and radioresistant breast
cancer MCF7-R cells as well as lung cancer H358-R and H157-R cells
could also be enhanced by STAT3 inhibition (Supplementary Fig. 5B).
However, the activation of ERK1/2 cannot be induced by STAT3 in-
hibition in wild-type U251 and U87 cells, as well as wild-type U251
tumors in which the basal pSTAT3 (Y705) stayed at low levels
(Supplementary Figs. 5C–E).
To exclude possible oﬀ-target eﬀects of the inhibitors, we trans-
fected U251/C7 cells with vector, STAT3 (Y705F) mutant or STAT3 WT
(Supplementary Fig. 5F), followed by 5 Gy radiation treatment. No
diﬀerence of the basal ERK1/2 activation was observed in the three
diﬀerent cell lines. However, pERK1/2 was signiﬁcantly increased in
cells expressing STAT3 (Y705F) by radiation stimulation, while no al-
teration was found in those expressing endogenous STAT3 or trans-
fected with wild-type STAT3 (Fig. 3D), suggesting that the mutant
STAT3 (Y705F) competitively blocked the endogenous pSTAT3 (Y705)-
mediated inhibition of ERK1/2 activation. However, cells over-
expressing wild-type STAT3 were reversely increased with pERK1/2 by
inhibition of pSTAT3 (Y705), and the enhancement of pERK1/2 was
even higher than that in control cells in a time-dependent manner as
observed in H358-R and H157-R cells (Fig. 3E and Supplementary
Fig. 5G).
To determine how the increased pERK1/2 is generated, we em-
ployed Cycloheximide(CHX) to block protein synthesis in the presence
or absence of STAT3 inhibition. CHX alone reduced pSTAT3 (Y705) and
increased pERK1/2. Interestingly, pERK1/2 was further enhanced in
cells with an additional CHX administration whereby protein synthesis
inhibition combined with STAT3 inhibition completely depleted
pSTAT3 (Y705), indicating that the increased pERK1/2 with STAT3
blockade was originally modiﬁed from existing ERK1/2, not from
newly expressed proteins. In addition, ERK1/2 was further activated by
enhancing pSTAT3 (Y705) inhibition (Fig. 3F). Since ERK1/2 signaling
plays a critical mechanism for cell survival, we next blocked pSTAT3
(Y705) in U251/C7 cells and tested downstream proteins of ERK1/2
signaling including CBP, RSK-1, c-fos, c-Myc, Ets-1 and pGSK 3β (Ser9)
indicating that c-fos and c-Myc were signiﬁcantly upregulated. Con-
sistently, phosphorylated GSK 3β (Ser9), the inactive form of GSK 3β
known to upregulate β-catenin to promote tumor progression, was also
increased after STAT3 depletion, whereas these upregulations can be
reversely blocked by an additional ERK1/2 inhibition (Fig. 3G).
Considering ERK1/2 phosphorylation enhancement occurred no
longer than 0.5 h after cells incubated with STAT3 inhibitors, mutant
STAT3 (Y705) competitively impede wild-type STAT3-mediated ERK1/
2 phosphorylation inhibition, and ERK1/2 activation increased by en-
hancing the depletion of pSTAT3 (Y705), this information strongly
suggest that a complex consists of components containing at least
pSTAT3 (Y705) and ERK1/2 may exist in radioresistant cells. Although
STAT3 was previously reported to physically associate with ERK1/2
[29,47], it is not clear if pSTAT3 (Y705) can form complex with ERK1/2
in radioresistant GBM cells. Coimmunoprecipitation assay showed that
inhibition of pSTAT3 (Y705) markedly reduced its binding to ERK1/2
following with rapid increase of ERK1/2 phosphorylation
(Supplementary Figs. 6A and B). Collectively, these results suggest that
STAT3 inhibition releases ERK1/2 from the complex for phosphoryla-
tion to induce downstream oncogenic signaling as a potential com-
pensation bypass for tumor cell survival.
3.5. Dual blockade of STAT3 and ERK1/2 sensitizes GBM cells to radiation
in vitro and in vivo
To evaluate whether inhibition of both STAT3 and ERK1/2 could
achieve a more eﬃcient anti-radioresistant eﬀect in GBM, we seeded
U251/C7 cells for 24 h, and supplemented with medium containing
STAT3 inhibitors cryptotanshinone, WP1066 or S3I-201 combined with
or without MEK1/2 inhibitor U0126. Compared with cells administered
with STAT3 inhibitors alone, cells challenged with a combination
treatment of STAT3 and ERK1/2 inhibition were almost completely
eliminated by radiation, in which both of pSTAT3 (Y705) and pERK1/2
were almost depleted (Fig. 4A and B and Supplementary Fig. 7A). Since
STAT3 inhibitors may have oﬀ-target eﬀects, we employed STAT3-
knockout #2 and #3 cells derived from U251/C7 to verify the eﬀect.
#3 cells were rescued with vector, mutant STAT3 (Y705F) or wild-type
STAT3, respectively. And #2 cells were rescued with STAT3 (Y705F) or
wild-type STAT3. Each of them was exposed to DMSO, MEK1/2 in-
hibitors U0126 or selumetinib followed by sham or 5 Gy radiation
treatment. Consistently, in the presence of inhibitors of ERK1/2 sig-
naling, radiation completely eradicated the STAT3 knockout cells re-
constituted with vector or STAT3 (Y705F). In the absence of ERK1/2
inhibition, radiation could not eﬃciently eliminated cells, especially
those expressing wild-type STAT3 (Fig. 4C).
We next examined the eﬀect of STAT3 and ERK1/2 inhibition on
apoptosis induced by radiation. Cells were exposed to 5 Gy radiation
plus cryptotanshinone to inhibit STAT3 activation for 48 h. Agreeing
with the cell morphology alteration shown in Supplementary Fig. 7B,
cell death was increased by radiation from 6.14% (sham) to 11.56%
(5 Gy) in the absence of cryptotanshinone, while increased from
14.31% (sham) to 19.13% (5 Gy) in the presence of STAT3 inhibition,
suggesting that STAT3 inhibition synergized with radiation to slightly
increase cell death. Importantly, cell death could be signiﬁcantly en-
hanced from 35.45% (sham) to 43.78% (5 Gy), or 24.97% (sham) to
29.53% (5 Gy) via an additional ERK1/2 inhibition. No signiﬁcant
diﬀerence was observed in cell death between DMSO incubated cells
and those applied selumetinib (from 7.63% to 14.98%) or U0126 (from
7.5% to 15.58%) alone (Fig. 4D and E and Supplementary Fig. 7C).
These observations were further conﬁrmed by measuring the level of
cleaved-caspase3 (Fig. 4F). Taken together, our results indicate that
blocking STAT3 inhibition-induced ERK1/2 activation could achieve a
more eﬃcient eradication of radioresistant GBM cells.
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To address whether combinational inhibition of STAT3 and ERK1/2
signaling can sensitize radioresistant GBM tumors in vivo. Wild-type
U251 cells were subcutaneously injected into nude mice. Tumors
reached 200mm3 after 16 days inoculation and were exposed to frac-
tionated local RT (2 Gy per day for 5 days). Tumors regressed but re-
growth was observed post- RT at day 28. Cryptotanshinone and
Selumetinib were then intratumorally injected singly or in combination
following a second fractionated RT (2 Gy per day for 2 days). Inhibitors
were administered every other day till the end of experiment. After RT,
continuous combinative administration of STAT3 and ERK1/2 in-
hibitors was eﬃcacious in shrinking and delaying tumor regrowth,
whereas single agent, on the other hand, revealed limited eﬀect on
tumor growth (Fig. 5A–C). In addition to the eﬀect on tumor inhibition,
dual administration of inhibitors did not lead to signiﬁcant mice body
weight loss (Fig. 5D). Consistently, dual blockade of STAT3 and ERK1/2
showed the most eﬀective inhibition on the viability of resistant GBM
cells while no signiﬁcant alteration of cell viability was observed in
human astrocytes (Supplementary Fig. 8). IHC staining of tumor tissues
(caption on next page)
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from diﬀerent groups demonstrated enhanced ERK1/2 phosphorylation
by STAT3 inhibition which could be blocked via an additional admin-
istration of MEK1/2 inhibitor. Combinative inhibition of pSTAT3
(Y705) and pERK1/2 eﬃciently initiated caspase 3 cascades in the
presence of RT (Fig. 5E). Taken together, these ﬁndings suggest that
ERK1/2 signaling activation due to blocking pSTAT3 (Y705) reﬂect the
heterogenic cancer cells in solid tumor RT, thus dual blockade of STAT3
and ERK1/2 is a potential eﬃcient strategy to sensitize resistant GBM
cells to RT (Supplementary Fig. 9).
4. Discussion
Tumor acquired radioresistance remains a major challenge in GBM
therapy. The current study reveals a previously unknown heterogenetic
feature of radioresistant GBM cells that can survive radiation with
STAT3 deﬁciency due to ERK1/2 activation. This ﬁnding is highly in-
formative for understanding the mechanistic insights of GBM resistance
and suggests a potentially eﬀective strategy to sensitize resistant GBM
cells to radiation by blocking STAT3 and ERK1/2 activation.
With the advent of powerful techniques, optimized preclinical
models and increased armory of antitumor drugs, there have now been
unprecedented opportunities to unveil the mechanisms of and over-
come GBM radioresistance through rational clinical assessments of
combinational approaches and developing predictive biomarkers to
enable precise patient stratiﬁcation. STAT3, an oncogenic transcription
factor, has been extensively studied and well-deﬁned in cancer re-
sponses to therapy and a promising target in cancer treatment [15,16].
STAT3 is shown to be required for maintenance of the stemness of cells
derived from human GBM tumor specimens [12] and blocking of STAT3
depleted multipotency, but could not induce apoptosis in GBM stem
cells, of which the underlying mechanisms remain unclear. Here we
reveal that the radioresistant GBM cells derived from clinically mimic
fractionated radiation were enriched with stemness markers which
agreed with the recurrent GBM post RT. However, surprisingly, al-
though STAT3 inhibition or even gene deﬁciency inhibited the majority
of cells, a fraction of cells survived from radiation with STAT3 blockade
with ERK1/2 activation. In comparison with cells with STAT3 inhibi-
tion or CRISPR/cas9-mediated STAT3 knockout, no much diﬀerence of
CD133 expression was observed in radioresistant GBM cells without
treatment, implying that radioresistant GBM cells were able to main the
stemness after STAT3 was blocked. Furthermore, tumor spheres grown
in medium containing STAT3 inhibitors revealed lager size than those
incubated with DMSO. Mechanistic studies demonstrated that ERK1/2
signaling was activated to promote cell survival after pSTAT3 (Y705)
was blocked in radioresistant cells. An additional administration of
ERK1/2 inhibition could help to eradicate the cells survived STAT3
inhibition and radiation treatment. These results demonstrate a pre-
viously unknown heterogenetic GBM cells in which ERK1/2 is essential
for surviving not only radiation but also when STAT3 signaling
pathway is blocked.
This work further supports the notion that targeting existing
activated oncogenic pathways may not achieve eﬃcient anti-tumor
eﬀects. A variety of mechanisms involving in drug resistance have been
identiﬁed in diverse cancer models [48]. Interleukin 6 (IL-6), a multi-
functional cytokine regulating cell proliferation and survival through
STAT3, was reported to release in the thymus in response to doxor-
ubicin treatment, leading to the survival of lymphoma cells and ulti-
mately patient relapse [49]. Blockade of ERBB2 activated MEK-ERK1/2
signaling was found in ERBB2-ampliﬁed breast cancer cells in a HGF-
dependent manner [50]. Here, we show that radioresistant GBM cells
survive from the combination of radiation and STAT3 blockade via an
oncogenic bypass: enhancing ERK1/2 signaling activation, a hidden
mechanism unperceived in GBM therapeutic resistance. Our data sug-
gest that this mechanism may be a general “escape-route” for cancers
subjected to RT, such as GBM, breast cancer and lung cancer cells.
Another observation potentially related to the clinical scenario is
that pSTAT3 (Y705) competitively inhibit ERK1/2 and pSTAT3 (Y705)
inhibition activates ERK1/2 leading to disrupt the therapeutic eﬃcacy
of STAT3 inhibitors. Accumulating evidence suggests that ERK1/2
signaling can be activated by series inhibitors targeting other onco-
proteins essential for tumor progression. ERK1/2 signaling in lung
cancer cells with wild-type BRAF can be activated by RAF inhibitors in
a RAS-dependent manner [27,51]. RAF inhibitors accelerated the
growth of HRAS Q61L-mutant cells of skin-cancer lesions from patients
by re-activating ERK1/2 signaling, this growth can be blocked by an
additional use of MEK inhibitor [52]. Paradoxical hyperactivation of
ERK1/2 signaling was also observed in RAS-mutant leukemia in mela-
noma patient received BRAF Inhibitor vemurafenib, and was reported
to accelerate the proliferation of leukemic cells and reversed by drug
withdraw [53]. Additionally, STAT3 activation was triggered by MEK
inhibitors administration in an array of oncogene-addicted cancer cells
through FGFR and IL-6 signaling and signiﬁcantly limits the therapeutic
eﬃcacy. Disrupting STAT3 feedback activation improved the eﬃcacy of
MEK inhibition in vitro and in vivo [20].
In summary, our ﬁndings reveal that blocking STAT3 activation
with either inhibitors or site mutation activates pro-survival ERK1/2
signaling to prevent cells from apoptosis induced by a combination of
STAT3 inhibition and radiation. It is notable that resistant GBM cells
and regrown tumors post RT, which actively engage the ERK1/2 acti-
vation upon STAT3 inhibition, can be signiﬁcantly sensitized to an
additional ERK1/2 inhibition. Thus, radiation combined with dual
blockage of STAT3 and ERK1/2 is a potential eﬀective approach for
GBM therapy.
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Fig. 3. STAT3 inhibition activates ERK1/2 signaling. (A) Immunoblotting of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells treated with cryptotanshinone
(10 μM) for 0, 0.5, 2 or 4 h. (B) Left, representative immunoﬂuorescence of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells treated with DMSO or cryptotanshinone
(10 μM) for 4 h. Right, ﬂuorescence intensity of pSTAT3 (Y705) (red box) and pERK1/2 (green box) in cells treated with or without Cryptotanshinone were quantiﬁed
by ImageJ. Scale bar, 50 μm. (C) Immunoblotting of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells after exposure to STAT3 inhibitors SH5-07 (SH, 5 μM), S3I-201
(S3I, 50 μM), Stattic (10 μM) or WP1066 (WP, 5 μM) for 4 h, DMSO and STAT1 inhibitor Fludarabine (Fluid, 10 μM) were used as negative controls. (D)
Immunoblotting of pERK1/2 in U251/C7 cells transfected with vector, mutant (Y705F) or wild-type STAT3 (WT) 4 h after 5 Gy radiation. (E) Above, immunoblotting
of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells transfected with vector or wild-type STAT3 and treated with cryptotanshinone (10 μM) for 0.5 h or 4 h. Bottom, the
intensity of bands of pERK1/2 in cells transfected with or without wild type STAT3post incubation with Cryptotanshinone 0 h, 0.5 h or 4 h were quantiﬁed by ImageJ
for 4 times and normalized to α-tubulin. Mean ± SD, **P < 0.01, ***P < 0.001. (F) Above, immunoblotting of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells
treated with cryptotanshinone (10 μM) in the presence or absence of Cycloheximide (CHX, 20 μg/ml) for 4 h. Bottom, the intensity of bands of pSTAT3(Y705) and
pERK1/2 in cells treated with Cryptotanshinone in the presence or absence of CHX were quantiﬁed by ImageJ for 4 times and normalized to α-tubulin. Mean ± SD,
***P < 0.001, ****P < 0.0001. (G) Immunoblotting of CBP, RSK-1, c-fos, c-Myc, Ets-1, phosphorylated GSK 3β (Ser 9) and GSK 3β in U251/C7 cells incubated with
cryptotanshinone (10 μM) with or without MEK1/2 inhibitor selumetinib (selume, 1 μM) for 24 h. Data are representative of three independent experiment. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 4. Enhanced ERK1/2 activation mediates resistance to radiation in GBM cells. (A) Immunoblotting of pSTAT3 (Y705) and pERK1/2 in U251/C7 cells
exposed to cryptotanshinone (10 μM), WP1066 (5 μM) or S3I-201 (50 μM) for 4 h in the presence or absence of U0126 (10 μM; ERK1/2 inhibition). (B) Clonogenic
survival of U251/C7 cells. Brieﬂy, cells were incubated with cryptotanshinone (10 μM), WP1066 (5 μM) or S3I-201 (50 μM) for 4 h and then were exposed to 5 Gy
radiation. Mean ± SD, ***P < 0.001. (C) Left, clonogenicity of STAT3-knockout #3 cells rescued with vector, mutant STAT3 (Y705F) or wild-type STAT3, and
STAT3 knockout #2 cells rescued with mutant STAT3 (Y705F) or wild-type STAT3. Brieﬂy, cells were incubated with U0126 (5 μM) or selumetinib (selume, 1 μM;
ERK1/2 inhibition) and following with exposure to 5 Gy radiation. The survived clones were stained with crystal violet after 12 days cell culture. Right, quanti-
ﬁcation of the survived clones in each group. Data are shown as the mean values ± SD of triplicates, ***P < 0.001, ****P < 0.0001. (D) Western blot of pSTAT3
(Y705) and pERK1/2 in U251/C7 cells exposed to cryptotanshinone (10 μM) combined with or without U0126 (5 μM) or selumetinib (1 μM) for 4 h. (E) Annexin V-
FITC and propidium iodide (PI) staining inU251/C7 cells 48 h after exposure to 5 Gy radiation. Before radiation treatment, cells have been pretreated with
cryptotanshinone (10 μM) in the presence or absence of selumetinib (1 μM) or U0126 (10 μM) for 4 h. Mean ± SD of triplicates. *P < 0.05, **P < 0.01,
***P < 0.001 (student's t-test, two tailed). (F) Immunoblotting of cleaved-caspase3 in U251/C7 cells. U251/C7 cells pretreated with cryptotanshinone, selumetinib,
U0126 or indicated combinations for 4 h were exposed to 5 Gy radiation for further 24 h. Data are representative of three independent experiment.
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Fig. 5. Dual blockade of STAT3 and ERK1/2 inhibits the regrowth of irradiated GBM tumors. (A) Above, tumor regrowth and treatment model were generated
with 3×106 U251 cells subcutaneously transplanted into nude mice. When tumor volume reached 200 mm3local radiation was delivered 2 Gy per day for 5 days
(from Day 16 to Day 20). At day 28, IHC stain of CD133, pSTAT3 and pERK1/2 were performed in wild type or regrown tumors (bottom), and the regrown tumors
were treated with intratumoral injection of DMSO, Cryptotanshinone (Crypto, 25mg/kg), Selumetinib (Selume, 25mg/kg) or a combination of Crytotanshinone
(25mg/kg) and Selumetinib (25mg/kg), and subsequently were exposed to local RT (2 Gy per day for 2 days). Inhibitors were intratumorally injected every other
day till the end of experiment. (B) Tumor growth in nude mice with indicated treatments. Mean ± SD. **P < 0.01, ***P < 0.001 (student's t-test, two tailed).
Black arrow, RT; red arrow, inhibitor treatment. (C) Image of tumors in each group at the end of experiment (left; n= 7 in DMSO group, n=6 in Crypto group, n=5
in Selume group and n=7 in combination group). Tumor weights (right) and mice body weights (D) were also recorded. (E) HE stain, IHC stain and quantiﬁcation
of pSTAT3 (Y705), pERK1/2 and cleaved-caspase 3 (c-caspase 3) in xenografts from indicated groups. Scale bar, 100 μm. Mean ± SD, ns, no signiﬁcance,
**P < 0.01, ***P < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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